in accordance with SFAS No. 123R. We believe that excluding the
impact of expensing stock options better reflects the recurring
economic characteristics of our business.
(3) Other items - Non-GAAP net loss and diluted net loss per common
share exclude other unusual or non-recurring items that are evaluated
on an individual basis. Our evaluation of whether to exclude an item
for purposes of determining our non-GAAP financial measures considers
both the quantitative and qualitative aspects of the item, including,
among other things (i) its size and nature, (ii) whether or not it
relates to our ongoing business operations, and (iii) whether or not
we expect it to occur as part of our normal business on a regular
basis. Items excluded for purposes of determining non-GAAP net loss
and diluted net loss per common share include deemed dividends,
preferred stock accretion, and changes in the fair value of warrant
About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has two product candidates in Phase II clinical trials, Amigal(TM) for the treatment of Fabry disease and Plicera(TM) for the treatment of Gaucher disease. The Company is also conducting Phase I clinical trials of AT2220 for the treatment of Pompe disease.
Amicus cautions you that state
|SOURCE Amicus Therapeutics|
Copyright©2007 PR Newswire.
All rights reserved